H2AX and chronic myelogenous leukemia, BCR-ABL1 positive: Zangh and co-workers [65] reinforce that H2AFX dysfunction is considered one important event in cancer patients that develop resistance during treatment, including IM therapy, and demonstrated the importance of H2AFX in the apoptosis regulation process of CML cells.